Journal of diabetes science and technology|2025|Orrange S et al.|4 citations
PMID: 39655368
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: Previous studies have shown an increase in obesity prevalence in the inflammatory bowel disease (IBD) population. The popularity of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) has increased in recent years due to their effective…
Obesity is rising among women of reproductive age and significantly contributes to subfertility. If conception occurs, maternal obesity is associated with increased risks for both maternal and neonatal complications, with potential long-term effects…
The increasing prevalence of type 2 diabetes presents a major global health challenge. Glucagon-like peptide-1 (GLP-1) receptor agonists offer glycemic control, weight loss, and cardiovascular benefits but are limited by rapid enzymatic degradation a…
The STEP 1 randomized trial evaluated the effect of taking semaglutide versus placebo on body weight over a 68-week duration. As with any study evaluating an intervention delivered over a sustained period, nonadherence was observed. This was addresse…
Tau hyper-phosphorylation has been recognized as an essential contributor to neurodegeneration in Alzheimer's disease (AD) and related tauopathies. In the last decade, tau hyper-phosphorylation has gained considerable concern in AD therapeutic develo…
Glucagon-like peptide-1 receptor agonists are peptide analogues that are used to treat type 2 diabetes mellitus and obesity. The first medication in this class, exenatide, was approved in 2005, and these medications, specifically semaglutide, have be…
OBJECTIVE: Obesity management requires personalized approaches. Using data from the Aviitam platform in France, this study aimed to do the following: 1) explore psychological and behavioral patterns through clustering techniques; 2) validate the robu…
Obesity is a global health challenge associated with significant metabolic and cardiovascular risks. Bariatric surgery and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are effective interventions for weight loss and metabolic improvem…
Semaglutide and tirzepatide are two commonly prescribed glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonists used for the treatment of type 2 diabetes and chronic weight management. Allo…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are crucial in managing type 2 diabetes mellitus (T2DM) and obesity. Agents like dulaglutide, semaglutide, and liraglutide mimic endogenous GLP-1, enhancing insulin secretion and promo…
INTRODUCTION: Semaglutide injection 2.4 mg (Wegovy; hereafter referred to as semaglutide) was approved by the US Food and Drug Administration in June 2021 for chronic weight management in adults with overweight or obesity. This study aimed to evaluat…
Obesity management, whether lifestyle-based, pharmacological, or surgical, is frequently associated with gastrointestinal adverse effects (GI AEs) that may impact treatment adherence and patient quality of life. With the increasing use of incretin-ba…
PURPOSE: To report data on the real-world effectiveness and safety of injectable (IS) and oral (OS) therapies in obese or overweight diabetes (T2DM) patients on glycometabolic control, weight loss (WL) and weight maintenance after the use of semaglut…
GIM/FP/GP: [Formula: see text].
This article summarizes the key literature describing the effects of the pancreatic beta-cell hormone amylin on eating. One of the first described and best investigated effects of amylin on eating is its physiological effect to control meal size by i…